Literature DB >> 29049827

Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling.

Robert O Bonow1,2, Robert A Harrington3,4, Clyde W Yancy3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29049827     DOI： 10.1001/jamacardio.2017.3656

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  5 in total

Review 1.  T4 Translational Moonshot: Making Cardiovascular Discoveries Work for Everyone.

Authors:  John M Westfall; George A Mensah
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

Review 2.  Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment.

Authors:  Kazutoshi Sugiyama; Yoshifumi Saisho
Journal:  Diseases       Date:  2018-05-24

3.  Just Price for PCSK9 Inhibitors: No less, No More.

Authors:  Khurram Nasir
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

Review 4.  CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?

Authors:  Christian Abendstein Kjellmo; Anders Hovland; Knut Tore Lappegård
Journal:  Diseases       Date:  2018-05-27

5.  Reformulating Small Molecules for Cardiovascular Disease Immune Intervention: Low-Dose Combined Vitamin D/Dexamethasone Promotes IL-10 Production and Atheroprotection in Dyslipidemic Mice.

Authors:  Laura Ospina-Quintero; Julio C Jaramillo; Jorge H Tabares-Guevara; José R Ramírez-Pineda
Journal:  Front Immunol       Date:  2020-04-24       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.